SPPI Key Statistics, Chart & Performance
The current stock price of SPPI is 1.03 USD. In the past month the price increased by 7.29%. In the past year, price decreased by -2.83%.
SPPI Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.4 | 390.79B | ||
| AMGN | AMGEN INC | 14.98 | 176.45B | ||
| GILD | GILEAD SCIENCES INC | 14.87 | 151.07B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 27.01 | 118.98B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.64 | 83.43B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 777.72 | 52.40B | ||
| INSM | INSMED INC | N/A | 37.15B | ||
| NTRA | NATERA INC | N/A | 32.38B | ||
| BIIB | BIOGEN INC | 11.23 | 27.57B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.39 | 20.89B | ||
| INCY | INCYTE CORP | 16.67 | 21.01B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 21.57B |
Related stock screener links
About SPPI
Company Profile
Spectrum Pharmaceuticals, Inc. is a biotechnology company, which engages in the acquisition, development and commercialization of a pipeline of novel and targeted oncology therapies. The company is headquartered in Henderson, Nevada and currently employs 86 full-time employees. The firm is focused on acquiring, developing, and commercializing targeted oncology therapies. The firm's product portfolio consists of one commercial product and product candidates for the treatment of cancer patients. Its commercial product candidate includes ROLVEDON (eflapegrastim), which is a long-acting granulocyte colony-stimulating factor (G-CSF) that employs a proprietary LAPSCOVERY technology designed to enhance the duration of therapeutic effects and reduce the frequency of administration. ROLVEDON is FDA-approved for the treatment of adult patients with chemotherapy-induced neutropenia. Its development pipeline includes Poziotinib is a novel, pan-HER inhibitor that is designed to irreversibly block signaling through the Epidermal Growth Factor Receptor (EGFR) family of TKIs, including HER1 (erbB1; EGFR), HER2 (erbB2), HER4 (erbB4), and HER receptor mutations.
Company Info
SPECTRUM PHARMACEUTICALS INC
11500 S Eastern Ave Ste 240
Henderson NEVADA 89052 US
CEO: Joseph W. Turgeon
Employees: 86
Phone: 17028356300.0
SPECTRUM PHARMACEUTICALS INC / SPPI FAQ
What does SPECTRUM PHARMACEUTICALS INC do?
Spectrum Pharmaceuticals, Inc. is a biotechnology company, which engages in the acquisition, development and commercialization of a pipeline of novel and targeted oncology therapies. The company is headquartered in Henderson, Nevada and currently employs 86 full-time employees. The firm is focused on acquiring, developing, and commercializing targeted oncology therapies. The firm's product portfolio consists of one commercial product and product candidates for the treatment of cancer patients. Its commercial product candidate includes ROLVEDON (eflapegrastim), which is a long-acting granulocyte colony-stimulating factor (G-CSF) that employs a proprietary LAPSCOVERY technology designed to enhance the duration of therapeutic effects and reduce the frequency of administration. ROLVEDON is FDA-approved for the treatment of adult patients with chemotherapy-induced neutropenia. Its development pipeline includes Poziotinib is a novel, pan-HER inhibitor that is designed to irreversibly block signaling through the Epidermal Growth Factor Receptor (EGFR) family of TKIs, including HER1 (erbB1; EGFR), HER2 (erbB2), HER4 (erbB4), and HER receptor mutations.
What is the current price of SPPI stock?
The current stock price of SPPI is 1.03 USD.
Does SPPI stock pay dividends?
SPPI does not pay a dividend.
What is the ChartMill rating of SPECTRUM PHARMACEUTICALS INC stock?
SPPI has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Is SPECTRUM PHARMACEUTICALS INC (SPPI) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on SPPI.
SPPI Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to SPPI. When comparing the yearly performance of all stocks, SPPI is a bad performer in the overall market: 61.3% of all stocks are doing better.
SPPI Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to SPPI. SPPI has a bad profitability rating. Also its financial health evaluation is rather negative.
SPPI Financial Highlights
Over the last trailing twelve months SPPI reported a non-GAAP Earnings per Share(EPS) of -0.36. The EPS increased by 58.62% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 1.08 |
SPPI Forecast & Estimates
10 analysts have analysed SPPI and the average price target is 1.29 USD. This implies a price increase of 24.78% is expected in the next year compared to the current price of 1.03.
For the next year, analysts expect an EPS growth of 88.67% and a revenue growth 722.64% for SPPI